Clinicopathological features and treatment outcomes in Ewing's sarcoma patients: A 10-year experience of Alexandria clinical oncology department
Background: Ewing's sarcoma (ES) is an aggressive tumor, which is usually associated with micrometastases in the circulation. Thus, systemic chemotherapy in addition to local control modality is essential to improve outcomes. The aim of this study was to evaluate clinicopathological features an...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2017-01-01
|
| Series: | Indian Journal of Medical and Paediatric Oncology |
| Subjects: | |
| Online Access: | http://www.ijmpo.org/article.asp?issn=0971-5851;year=2017;volume=38;issue=3;spage=316;epage=320;aulast=Nazeer |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849324900248977408 |
|---|---|
| author | Asmaa Nazeer Alaa Kandil Omar Zahra Maher Soliman |
| author_facet | Asmaa Nazeer Alaa Kandil Omar Zahra Maher Soliman |
| author_sort | Asmaa Nazeer |
| collection | DOAJ |
| description | Background: Ewing's sarcoma (ES) is an aggressive tumor, which is usually associated with micrometastases in the circulation. Thus, systemic chemotherapy in addition to local control modality is essential to improve outcomes. The aim of this study was to evaluate clinicopathological features and treatment outcomes in patients with ES. Materials and Methods: Medical files of 74 patients with nonmetastatic ES treated at our centers between 2004 and 2014 were retrospectively evaluated. The clinicopathological parameters were extracted and statistically correlated with event-free survival (EFS) and overall survival (OS). Results: The median age of patients was 13 years. The median follow-up duration was 63.8 months. About two-thirds (58.1%) of patients were male. Pain (74.3%) was the most common presenting symptom. Extremities (48.6%) were the frequently affected sites. Thirty-two patients (43.2%) presented by tumors larger than 8 cm. All patients were treated with chemotherapy. Local therapies were surgery and/or radiotherapy. The 5-year EFS and OS were 44% and 57%, respectively. On multivariate analysis, EFS and OS were significantly associated with age, tumor site, and tumor size. Conclusions: Despite limited resources in a developing country, the survival rates of ES are comparable to that in developed countries, and prognostic factors are age, tumor site, and tumor size. |
| format | Article |
| id | doaj-art-e5a06bea7f9b4c24b33ee33aa5eedf78 |
| institution | Kabale University |
| issn | 0971-5851 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Thieme Medical and Scientific Publishers Pvt. Ltd. |
| record_format | Article |
| series | Indian Journal of Medical and Paediatric Oncology |
| spelling | doaj-art-e5a06bea7f9b4c24b33ee33aa5eedf782025-08-20T03:48:32ZengThieme Medical and Scientific Publishers Pvt. Ltd.Indian Journal of Medical and Paediatric Oncology0971-58512017-01-0138331632010.4103/ijmpo.ijmpo_107_17Clinicopathological features and treatment outcomes in Ewing's sarcoma patients: A 10-year experience of Alexandria clinical oncology departmentAsmaa NazeerAlaa KandilOmar ZahraMaher SolimanBackground: Ewing's sarcoma (ES) is an aggressive tumor, which is usually associated with micrometastases in the circulation. Thus, systemic chemotherapy in addition to local control modality is essential to improve outcomes. The aim of this study was to evaluate clinicopathological features and treatment outcomes in patients with ES. Materials and Methods: Medical files of 74 patients with nonmetastatic ES treated at our centers between 2004 and 2014 were retrospectively evaluated. The clinicopathological parameters were extracted and statistically correlated with event-free survival (EFS) and overall survival (OS). Results: The median age of patients was 13 years. The median follow-up duration was 63.8 months. About two-thirds (58.1%) of patients were male. Pain (74.3%) was the most common presenting symptom. Extremities (48.6%) were the frequently affected sites. Thirty-two patients (43.2%) presented by tumors larger than 8 cm. All patients were treated with chemotherapy. Local therapies were surgery and/or radiotherapy. The 5-year EFS and OS were 44% and 57%, respectively. On multivariate analysis, EFS and OS were significantly associated with age, tumor site, and tumor size. Conclusions: Despite limited resources in a developing country, the survival rates of ES are comparable to that in developed countries, and prognostic factors are age, tumor site, and tumor size.http://www.ijmpo.org/article.asp?issn=0971-5851;year=2017;volume=38;issue=3;spage=316;epage=320;aulast=NazeerChemotherapyEwing's sarcomaprognosissurvival |
| spellingShingle | Asmaa Nazeer Alaa Kandil Omar Zahra Maher Soliman Clinicopathological features and treatment outcomes in Ewing's sarcoma patients: A 10-year experience of Alexandria clinical oncology department Indian Journal of Medical and Paediatric Oncology Chemotherapy Ewing's sarcoma prognosis survival |
| title | Clinicopathological features and treatment outcomes in Ewing's sarcoma patients: A 10-year experience of Alexandria clinical oncology department |
| title_full | Clinicopathological features and treatment outcomes in Ewing's sarcoma patients: A 10-year experience of Alexandria clinical oncology department |
| title_fullStr | Clinicopathological features and treatment outcomes in Ewing's sarcoma patients: A 10-year experience of Alexandria clinical oncology department |
| title_full_unstemmed | Clinicopathological features and treatment outcomes in Ewing's sarcoma patients: A 10-year experience of Alexandria clinical oncology department |
| title_short | Clinicopathological features and treatment outcomes in Ewing's sarcoma patients: A 10-year experience of Alexandria clinical oncology department |
| title_sort | clinicopathological features and treatment outcomes in ewing s sarcoma patients a 10 year experience of alexandria clinical oncology department |
| topic | Chemotherapy Ewing's sarcoma prognosis survival |
| url | http://www.ijmpo.org/article.asp?issn=0971-5851;year=2017;volume=38;issue=3;spage=316;epage=320;aulast=Nazeer |
| work_keys_str_mv | AT asmaanazeer clinicopathologicalfeaturesandtreatmentoutcomesinewingssarcomapatientsa10yearexperienceofalexandriaclinicaloncologydepartment AT alaakandil clinicopathologicalfeaturesandtreatmentoutcomesinewingssarcomapatientsa10yearexperienceofalexandriaclinicaloncologydepartment AT omarzahra clinicopathologicalfeaturesandtreatmentoutcomesinewingssarcomapatientsa10yearexperienceofalexandriaclinicaloncologydepartment AT mahersoliman clinicopathologicalfeaturesandtreatmentoutcomesinewingssarcomapatientsa10yearexperienceofalexandriaclinicaloncologydepartment |